Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - University

University

Mostafa Chamekh, Professor (coordinator of the project) - Georges Casimir, Professor - Francis Corazza, Professor- David de Bels, Doctor

ULB - Royal Academy of Medicine of Belgium
" The project aims at understanding why men are more affected than women. Compelling evidences indicate sex-bias in SARS-CoV2 with male representing the majority of severe cases requiring intensive care. Excessive inflammatory symptoms attributed mainly to cytokine storm is the hall-mark of disease progress. We ask whether differences in genetic fitness between male and female patients could contribute to sex-bias and we focus, in particular, on potential role of microRNAs in fine tuning the type and magnitude of the inflammatory response "
Funding: Current application to FNRS IRIS research
Publication References: - Chamekh M, M Deny, M Romano, et al. Differential Susceptibility to Infectious Respiratory Diseases between Males and Females Linked to Sex-Specific Innate Immune Inflammatory Response. Front Immunol. 2017; 8: 1806. - Casimir, G. J., Lefèvre, N., Corazza, F et al. J. Sex and inflammation in respiratory diseases : a clinical...

Mutien Garigliany, Professor - Daniel Desmecht, Professor

ULiège 
" There is a critical need for therapeutic solutions against SARS-CoV-2. Before implementing innovative treatments in human medicine, a first screening of the antiviral or immunomodulatory activity should be performed by in vitro and in vivo methods. To this aim, we developed in vitro (cell culture) and in vivo (hamsters and mice) models of SARS-CoV-2 infection. We developed an in vitro (cell culture) and in vivo (hamsters and mice) to screen antiviral or immunomodulatory molecules, in partnership with colleagues from the ULiège hospital and the GIGA research center. We also validate the inactivation protocols to facilitate the diagnostic workflow, in partnership with the Federal task force. "
Funding: Currently no funding. We applied to the "Crédits urgents de recherche" call.
Contact: Mutien Garigliany, DVM, PhD, Dipl. ECVP Professor Department of Pathology Faculty of Veterinary Medicine Centre for Fundamental and Applied Research for Animals & Health (FARAH) Liège...

Mutien Garigliany, Professor - Daniel Desmecht, Professor

FARAH - ULiège 
" As of today, one of the most promising therapeutic solutions against COVID-19 is the use of convalescent plasma. A subset of the antibodies present in this plasma are able to bind the surface proteins of the virus, chiefly the Spike (attachment) protein, and to neutralize the ability of viral particles to infect permissive cells. Upon request of the Red Cross and ULiège CHU hospital, we developed seroneutralization assays to determine the titers in neutralizing antibodies of convalescent plasma. In collaboration with KU Leuven (Rega) and ITM Antwerp, we just completed an interlaboratory ring test. We screen convalescent plasmas on a routine basis for the Croix Rouge and Rode Kruis. Only plasmas with a titer in neutralizing antibodies above the cut-off value will be used therapeutically. The scarcity of the scientific literature on the subject (only a few studies on the therapeutic use of convalescent plasmas are currently available) make it difficult to fix a cut-off...

Nicolas Franco, Doctor

UNamur
" Mathematical modelling of the covid-19 epidemic in Belgium (SIR-type models, age-structured, care centres consideration,...): monitoring, detection of new peak and scenario-based forecasting "
Publication References: Technical reports can be delivered on demand
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Comment: Collaboration with GEES members on the mathematical modelling of the covid-19 epidemic in Belgium

Nicolas Gillet, Associate professor

UNamur
" APOBEC3 enzymes are innate immune effectors acting against viruses. They act by introducing mutations in viral genomes. We investigate the restriction activity of the APOBEC3 proteins on SARS-CoV-2 replication dynamics. "
Funding: UNamur
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

O. Vandenberg, Pr. - N. Clumeck, Pr. - C. Montesinos, Pr. - N. Dauby, MD, PhD - C. Gilles, MD - C. Martin, MD - S. Van den Wijngaert, MD - A. Marchant, Pr. - D. Martiny, Pr. - S. De Wit, Pr.

LHUB-ULB - Royal Academy of Medicine of Belgium
" "The purpose of this study is to map the healthcare workers exposure risk in Saint-Pierre University Hospital by combining molecular methods with serological assays. In summary, the short-term objective is threefold: (1) Provide an estimate of the sero-prevalence at baseline among high-risk health care workers (2) Determine prospectively the incidence of new SARS-CoV-2 infections among high-risk health care workers (3) Estimate the healthcare worker exposure to the virus by serological data to help our five partner hospitals in their day-to-day management of the ongoing pandemic The mid-term objectives are: (1) Establish an accurate mapping of the spread of the virus among our population allowing to identify the chain of transmission, (2) Identify predictive immunological markers of susceptibility to infection and disease severity to inform vaccine strategies and, (3) Establish solid diagnosis algorithm that will help adequate lockdown...

Pascale Huynen, Dr

CHU of Liège
" The aim of this study is to search for the presence of antibodies against SARS-CoV-2 in the staff of CHU de Liège and University of Liège, and to follow the evolution of antibody levels on blood samples taken 1.5 and 3 months after the first sample. This will allow to : • carry out a COVID-19 seroprevalence study by assaying anti-SARS-CoV-2 antibodies in people in contact with patients, compared to a population of "negative control" subjects, at baseline and 1.5 and 3 months after the first testing ; • observe the evolution of antibody levels between samples; • highlight possible seroconversion between samples in asymptomatic persons "
Funding: Wallonia Region CHU of Liège University of Liège Fondation Léon Frédéricq
Contact: Dr Pascale Huynen, Dpt of Clinical Microbiology, CHU of Liège and University of Liège Prof Pierrette Melin, Dpt of Clinical Microbiology, CHU of Liège and University of Liège Prof Yves Beguin, Dpt of Hematology, CHU of Liège and University of...

Patrice Cani, FNRS Senior Research Associate - Leïla Belkhir, PhD - Jean Ruelle, PhD - Julien De Greef, MD- Benoit Kabamba, PhD - Vincent Haufroid, PhD - Laure Elens, PhD - Jean Cyr Yombi, MD

Cliniques universitaires Saint-Luc, UCLouvain
" The objective of our project is to describe the nasopharyngeal (NP) microbiota and virome of SARS-CoV-2 infected patients at diagnosis through unbiased nextgeneration sequencing analysis and to correlate microbiota and virome profile with COVID-19 infectious phenotype. At a second stage of our project, provided additional findings are raised, those data will be enriched by NP transcriptome analysis of infected patients, and background genomic determination. Integration of those data and analysis through systems biology approach will enable better understanding of multidirectional host-pathogen interactions. "
Funding: FNRS CUR requested. Additional funding will be requested for further steps.
Contact: Pr L.Belkhir This email address is being protected from spambots. You need JavaScript enabled to view it. 02/7642198 --- Pr P.Cani This email address is being protected from spambots. You need JavaScript enabled to view it.

Patrice Soumillion, Professor

UCLouvain
" We are designing bacteria that produces the essential protease of COVID-19 and whose activity is associated with sensitivity to a specific antibiotics. This bacteria is a powerful platform for screening potential inhibitors of the protease (the bacteria becomes resistant to the antibiotics if the protease is inhibited). We will use it to screen large combinatorial libraires of cyclic peptides that will be produced by the bacteria as well. "
Funding: Lab funds. FRNS grant application ongoing.
Contact: Patrice Soumillion Louvain Institute of Biomolecular Science and Technology, UCLouvain Place Croix du Sud 4-5 1348 Louvain-la-Neuve

Ph. DELVENNE, FNRS Research Director / Chef de service Anatomie pathologique - J. GUIOT, Chef de clinique Pneumologie - L. RENAUD, Chef de service Pneumologie - M. MOUTSCHEN, Chef de service Infectiologie- B. MISSET, Chef de service Soins Intensifs

ULiège, CHU - Royal Academy of Medicine of Belgium
" Nous faisons face à une pandémie d'infection COVID-19. Ce virus pathogène est source de complications pulmonaires aggravant fortement le pronostic de nos patients. De nos jours, tant les mécanismes physiopathologiques en cause que les marqueurs de sévérité de l'atteinte restent indéterminés. Il apparaît donc comme urgent de pouvoir identifier des marqueurs diagnostiques, pronostiques et prédictifs pour nos patients. Dans ce contexte, plusieurs voies rapidement explorables nous apparaissent comme critiques. Le but final de cette étude est de contribuer à une prise en charge plus ciblée des patients porteurs d'une infection au SRAS-Cov-2. "
Funding: Fonds Léon Frederic
Publication References: Dix publications représentatives : 1) Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting. HUMBLET C, GREIMERS R, DELVENNE P, DEMAN J, BONIVER J, DEFRESNE MP. J Natl Cancer Inst 88 (1996), 824-831. IF...

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Philippe PEIGNEUX, Professor - Peter SIMOR, Postdoc IF-ULB - Rebeca SIFUENTES, Aspirant FNRS - Ariadna ALBAJARA SAENZ, postdoctoral researcher

ULB, UR2NF - Neuropsychology and Functional Neuroimaging Research Unit affiliated at CRCN - Center for Research in Cognition and Neurosciences and UNI - ULB Neurosciences Institute - FNRS - Royal Academy of Sciences, Letters and Fine Arts of Belgium
" The aim of the study is to examine day-to-day associations between subjective sleep quality and daytime functioning during the large-scale confinement measures taken in Belgium given the current Covid-19 pandemic in Europe. In particular, we are interested in assessing the interplay between altered patterns of sleep timing, duration and quality, and daytime behaviour, cognition, and affect for 2 weeks during the confinement period. Longitudinal data are obtained in Belgium, Hungary and Spain "
Funding: internal resources
Publication References: ongoing project
Contact: Project : This email address is being protected from spambots. You need JavaScript enabled to view it., Peter Simor: This email address is being protected from spambots. You need JavaScript enabled to view it. Philippe Peigneux : This email address is being protected from spambots. You need JavaScript enabled to view it.

Pierre CLOSE, FNRS Research Associate - Francesca RAPINO, Doctor

GIGA-Institute, ULiège - FNRS
" In this project, we study the epitranscriptomic regulation of the SARS-CoV-2. Based on analyses of the viral genome, we investigate the cellular machineries required for the viral replicative cycle. Our goal is to identify possible viral vulnerabilities that can be exploited for the development of innovative anti-viral therapeutic strategies. We investigate possible new therapeutic opportunities based on the analyses of the viral genomic organization and evolution. We speculate that specific cellular machineries are needed to support the viral replicative cycle. Our goal is uncover new antiviral therapeutic strategies based on the viral epitranscriptomic regulation, mRNA translation and protein expression. "
Funding: WELBIO & ULIEGE
Publication References: Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, Sin O, Shostak, Schmitz S, Piepers J, Ghesquière B, Karim L, Charloteaux B, Jamart D, Florin A, Lambert C, Rorive A, Jerusalem G...

Pierre Morsomme, Professor - Henri-François Renard, Professor

UCLouvain - UNamur
" One of the key determining factors in viral infection is the entry of the virus into the host cells. Different CoVs including MHV, SARS-CoV and MERS-CoV have been consistently demonstrated to engage the endocytic pathway as the main mechanism for viral entry into a variety types of host cells. At present, the entry mechanisms and the implication of the endocytic pathway of the new emerging SARS-CoV-2 have not been reported directly. It is known that SARS-CoV-2 utilizes the same receptor of SARS-CoV, which is angiotensin converting enzyme II (ACE2) for viral entry into the host cells. Since SARS-CoV-2 also binds to the same ACE2 receptor as SARS-CoV it is highly possible that this new CoV utilizes the same endocytic pathway for entry into the host cells. Besides, a recent report suggests that SARS-CoV-2 invaded host cells via another route of CD147-spike protein. Our lab is studying the endocytosis mechanism of several plasma membrane receptors previously...

Pierre Smeesters, Professor

HUDERF and ULB
" Role of Children in Sars-Cov-2 transmission, Heath Care Worker protection, Paediatric epidemiology and disease burden "
Funding: FNRS funding under assessment.
Contact: Prof Pierre Smeesters Academic Children Hospital Queen Fabiola Molecular Bacteriology Laboratory, ULB This email address is being protected from spambots. You need JavaScript enabled to view it.

Pierre VAN DER BRUGGEN, Professor

UCLouvain 
"Des données récentes suggèrent qu'une réponse exacerbée du système immunitaire face au SARS-CoV-2 pourrait contribuer à l'aggravation des symptômes des patients placés en soins intensifs. Ce phénomène est bien connu des immunobiologistes. En effet, certains traitements d'immunothérapie du cancer visant à inhiber PD-1 et/ou CTL-4 ou à administrer des lymphocytes T autologues porteurs de récepteur chimérique (CAR-T cells) peuvent avoir des effets secondaires similaires à cet emballement de la réponse immunitaire, tels qu'une tempête cytokinique. Ces thérapies visent à restimuler les lymphocytes T CD8 dits « épuisés », qui se développent à la suite de la persistance d'un pathogène et de l'inflammation qu'il provoque, lors d'une infection virale chronique ou lors d'un cancer. Vu cette similitude entre les effets secondaires des traitements réactivateurs du système immunitaire et de la réaction de certains patients à l'infection par le SARS-CoV2, une identification du phénotype...

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11

info@COVID19-WB.be

Brussels & Wallonia against COVID19